Can Mounjaro reverse liver scarring?

In the phase 2 SYNERGY-NASH trial, 51% to 55% of people on tirzepatide improved by at least one fibrosis stage after 52 weeks, versus 30% on placebo. That is encouraging but not proof of reversal in routine care. Larger, longer trials are still needed to confirm the effect.

Is NAFLD the same thing as MASLD?

Mostly yes. MASLD replaced NAFLD in 2023, and most people with NAFLD meet the new definition. The new name requires at least one cardiometabolic risk factor, such as excess weight, high blood sugar or high blood pressure.

Will insurance cover Mounjaro for fatty liver?

Mounjaro is approved for type 2 diabetes, not fatty liver, so coverage usually depends on a diabetes diagnosis. Using it only for MASH would be off-label, and insurers often decline off-label claims. Check with your plan before you assume coverage.

Is Mounjaro safe if I already have liver disease?

The phase 2 MASH trial reported mostly mild or moderate gastrointestinal side effects, similar to other tirzepatide studies. The trials excluded people with cirrhosis, so data in advanced liver disease are limited. A hepatologist should guide use if you have significant scarring.

How fast does liver fat drop on tirzepatide?

The SURPASS-3 MRI substudy measured liver fat at 52 weeks, when it had fallen by about 8 percentage points on the higher doses. The study did not report an exact timeline for when the drop began. Liver fat changes tend to track with weight loss.

Does Mounjaro Help Fatty Liver Disease (MASLD or MASH)?

The short answer: Mounjaro (tirzepatide) shows strong early results in fatty liver disease, but it is not FDA-approved to treat it. In a phase 2 biopsy trial, up to 62% of people on tirzepatide had their steatohepatitis resolve at 52 weeks, compared with 10% on placebo. A large phase 3 outcomes trial is now running. Today, the only FDA-approved MASH drugs are Rezdiffra (resmetirom) and Wegovy (semaglutide).

What are MASLD and MASH, and why did the names change?

MASLD stands for metabolic dysfunction-associated steatotic liver disease. It is the new name for what doctors used to call nonalcoholic fatty liver disease, or NAFLD. MASH, metabolic dysfunction-associated steatohepatitis, replaced NASH. MASH is the more serious form, where fat in the liver comes with inflammation and liver cell injury that can lead to scarring (fibrosis).

The change came from a 2023 multisociety Delphi consensus statement led by three large liver associations. In total, 236 experts and patient advocates from 56 countries took part. Their reasons were practical:

The old names defined the disease by what it was not ("nonalcoholic"), not by what causes it.
61% of respondents felt "nonalcoholic" was stigmatizing, and 66% felt the same about "fatty."
The new definition requires fat in the liver plus at least 1 of 5 cardiometabolic risk factors, such as excess weight, high blood sugar or high blood pressure.

The panel also created a middle category, MetALD, for people with MASLD who drink more alcohol (140 to 350 g a week for women, 210 to 420 g a week for men). This matters on Mounjaro, because alcohol and metabolic risk can both damage the liver. Our guide to Mounjaro and alcohol covers that overlap.

The condition is common. NIDDK estimates that about 24% of U.S. adults have the fatty liver form and 1.5% to 6.5% have the steatohepatitis form.

What did the tirzepatide liver biopsy trial find?

The key study is SYNERGY-NASH, a phase 2 trial published in the New England Journal of Medicine in 2024. It enrolled 190 adults with biopsy-confirmed MASH and moderate or severe (F2 or F3) fibrosis. Participants got weekly tirzepatide at 5 mg, 10 mg or 15 mg, or placebo, for 52 weeks. Everyone had a second liver biopsy at the end.

The primary goal was resolution of MASH without worse fibrosis. The results were:

Placebo: 10%
Tirzepatide 5 mg: 44%
Tirzepatide 10 mg: 56%
Tirzepatide 15 mg: 62%

All three doses beat placebo (P<0.001). Improvement of at least one fibrosis stage without worse MASH was a key secondary goal. It occurred in 30% on placebo and in 51% to 55% on tirzepatide. The fibrosis gains were real but less dramatic, with confidence intervals that came close to zero.

The authors were careful in their conclusion. They wrote that "larger and longer trials are needed" to confirm efficacy and safety. The most common side effects were gastrointestinal, and most were mild or moderate. That matches the general Mounjaro side effect profile.

Does Mounjaro lower liver fat in people with type 2 diabetes?

Yes, based on an MRI substudy of the phase 3 SURPASS-3 trial, published in Lancet Diabetes & Endocrinology in 2022. It included 296 adults with type 2 diabetes and a high fatty liver index. They got tirzepatide or insulin degludec, and liver fat was measured by MRI-PDFF (an MRI method that measures the fat fraction of the liver).

Average liver fat at the start was 15.7%. After 52 weeks, the pooled 10 mg and 15 mg tirzepatide groups dropped by an absolute 8.1 percentage points. The insulin group dropped by 3.4 points. The difference was 4.7 points in favor of tirzepatide.

Larger liver fat drops tracked with larger drops in belly fat and body weight. This fits the idea that much of the liver benefit comes from weight loss. A 2026 post hoc analysis found that the PNPLA3 I148M gene variant, a common genetic driver of fatty liver, did not seem to blunt this effect. Note one limit: this substudy measured fat, not inflammation or scarring. It cannot show that tirzepatide treats MASH on its own.

Is Mounjaro FDA-approved for fatty liver disease?

No. The current Mounjaro prescribing information lists two uses. One is glycemic control in type 2 diabetes for adults and children 10 and older. The other is reducing the risk of major cardiovascular events in adults with type 2 diabetes at high risk. The label does not mention MASLD, MASH or fatty liver.

Two other drugs do carry a MASH approval. Both cover adults with noncirrhotic MASH and moderate to advanced (F2 to F3) fibrosis, used with diet and exercise:

Rezdiffra (resmetirom), a once-daily pill, got accelerated approval on March 14, 2024. It was the first MASH drug the FDA approved.
Wegovy (semaglutide 2.4 mg) added a MASH indication on August 15, 2025, per the FDA approval record. The Wegovy label states this is an accelerated approval, and continued approval may depend on confirmatory results.

Wegovy's approval rests on part 1 of the phase 3 ESSENCE trial. At 72 weeks, steatohepatitis resolved in 62.9% on semaglutide versus 34.3% on placebo. Fibrosis improved in 36.8% versus 22.4%. For more on the semaglutide side, see ozempic.md. Do not compare the tirzepatide and semaglutide numbers head to head. The trials differed in size, length and phase.

Is there a phase 3 tirzepatide trial for liver disease?

Yes. Eli Lilly is running SYNERGY-OUTCOMES (NCT07165028), a phase 3 master protocol that began in October 2025. It tests tirzepatide and retatrutide against placebo in about 4,500 adults with high-risk MASLD.

This trial asks a harder question than SYNERGY-NASH. Instead of biopsy changes, it tracks major adverse liver outcomes. These include progression to cirrhosis, varices, fluid buildup (ascites), liver-related confusion, liver transplant and death. The trial will run about 224 weeks. Its primary completion is estimated for August 2030, so results are years away.

Enrollment uses non-invasive tests, not biopsies. People need at least 8% liver fat plus elevated stiffness and blood-marker scores. This design reflects a broader shift in hepatology away from routine liver biopsy.

Should someone with fatty liver ask about Mounjaro?

If you have type 2 diabetes and MASLD, Mounjaro is already an approved option for your diabetes. The liver data are a reasonable point to raise with your doctor. If you do not have diabetes, Mounjaro is not approved for you. Zepbound, the same drug under a different brand, is approved for weight management and obstructive sleep apnea, not MASH. Our Mounjaro vs Zepbound guide explains the difference.

Weight loss remains the core treatment for fatty liver, with or without drugs. NIDDK notes that losing 3% to 5% of body weight can reduce liver fat. Losing 7% to 10% may be needed to reduce inflammation and fibrosis. Tirzepatide commonly produces weight loss at or beyond those levels, as our Mounjaro weight loss results page shows.

Some points to discuss with a liver specialist or primary care doctor:

Your fibrosis stage, usually estimated with a blood score (FIB-4) or a liver stiffness scan.
Whether an approved MASH drug fits better if you have F2 or F3 fibrosis.
Alcohol intake, since MetALD changes the picture.
Whether you have cirrhosis. None of these drugs is approved for cirrhotic MASH.

The bottom line

Mounjaro clearly lowers liver fat, and a phase 2 biopsy trial showed MASH resolution in 44% to 62% of people, versus 10% on placebo. It is still not FDA-approved for MASLD or MASH. Rezdiffra and Wegovy hold that approval today. The phase 3 SYNERGY-OUTCOMES trial will show whether tirzepatide prevents cirrhosis and other serious liver events, but not until around 2030. If you have fatty liver, ask your doctor about your fibrosis stage first, then about treatment.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk with your doctor or a hepatologist before starting or changing any treatment for fatty liver disease.